| Gene name: | CDK2 |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | Phoenix-Eco |
| Experiment: | SA-β-gal activity assay//Western blot//Immunohistochemistry//Immunofluorescence |
| Description: | Although samples from both CVT2584- and vehicle-treated mice showed a certain degree of positivity, the SA-β-gal staining was significantly increased in spleens from CVT2584-treated mice, as quantitated in Figure 5. We also examined the presence of senescence-associated heterochromatin foci (SAHF), using an antibody directed against H3K9me3. Immunofluorescence staining of spleen tissue from CVT2584-treated mice showed a strong increase in SAHF formation compared to the vehicle-treated mice. Nuclear p19ARF-positive cells were readily detected in sections of CVT2584-treated animals but found virtually absent in the analyzed specimens from vehicle-treated animals. Nuclear p19ARF-positive cells were readily detected in sections of CVT2584-treated animals but found virtually absent in the analyzed specimens from vehicle-treated animals. |
| Target gene: | MYC |
| Official symbol(s): | MYC |
| R-AG-Target gene: | Upregulation |
| Subcategory: | Phosphorylation |
| Target gene experiment: | Western blot |
| Target gene description: | In agreement with our previous report, reduced MYC Ser-62 phosphorylation was observed in CVT2584-treated compared with vehicle-treated animals, both at lower and higher doses of CVT2584, supporting the notion that CDK2 regulates MYC phosphorylation in vivo. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...